When a company reports an 'efficacy estimate,' it often excludes patients who dropped out of a trial, inflating perceived success. Investors should demand the 'treatment regimen estimate,' which includes all participants and aligns with what the FDA actually considers for drug approval.

Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

To frame its trial results positively, Compass Pathways used less stringent definitions for key endpoints. It defined 'clinically meaningful reduction' and 'remission' at levels below the common standard, a tactic that calls into question the true magnitude of the drug's benefit.

Despite reporting positive Phase 2 asthma data that met the company's stated goals for 12-week dosing, Upstream Bio's stock dropped significantly. The CEO attributes this to the 24-week dosing data being less robust on the primary endpoint, highlighting the gap between achieving clinical goals and meeting nuanced market expectations for a best-case scenario.

Wave Life Sciences' drug candidate reduced harmful visceral fat but failed to achieve significant overall body weight loss, a key FDA approval criterion. This outcome suggests that novel mechanisms targeting specific fat types, while scientifically interesting, are commercially unviable if they don't also deliver on the primary endpoint that regulators and patients expect.

In an era of scientific skepticism, companies must clearly separate general biomedical education from product-specific promotional data. Blurring these lines undermines their role as credible stewards of science, deepens the patient trust gap, and makes them appear self-serving rather than educational.

Biotech firms are beginning to selectively disclose clinical data, citing the need to protect R&D from fast-following competitors, particularly from China. This forces investors into a difficult position: either trust management without full transparency or discount the company's value due to the opacity.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.